Chronic Kidney Disease News

Patients with chronic kidney disease who received medication to treat their depression did not see a reduction in adverse health risks for hospitalizations and mortality, a recently published study shows.

Use of the drug semaglutide in patients with type 2 diabetes significantly reduced the risk of major kidney disease events, cardiovascular outcomes and all-cause mortality vs. placebo, newly published data show.

Men were at greater risk for several complications associated with type 1 and type 2 diabetes compared with women, according to results published in the Journal of Epidemiology & Community Health.

LONG BEACH, Calif. — Hydralazine-induced autoimmune conditions may have a varied presentation, including drug-induced lupus or vasculitis, according to a speaker, here.

Proteinuria levels are not predictive of membranous lupus nephritis vs. proliferative lupus nephritis, according to data published in Rheumatology.

LONG BEACH, Calif. — Implementing medical nutrition therapy for patients with late-stage chronic kidney disease saved an estimated $47,000 per patient by delaying the need for dialysis, according to a poster presented here.

LONG BEACH, Calif. — A prognostic kidney test and medication management in patients with diabetic kidney disease was tied to use of cardiorenal protective medications and improved hypertension control, according to data presented here.

LONG BEACH, Calif. — Maximally titrated irbesartan and sparsentan each slowed kidney function decline compared with real-world and clinical trial standards of care, according to data presented here.

LONG BEACH, Calif. — Iptacopan may be superior to placebo in reducing proteinuria at 9 months, with early onset and effect consistency, according to data presented at the National Kidney Foundation Spring Clinical Meetings, here.

LONG BEACH, Calif. — Patients with heart failure who also experienced mitral regurgitation saw a doubling of their creatinine, according to data presented here.